Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
| 대상 질환 | Atopic Dermatitis, Eczema |
|---|---|
| 임상 단계 | 3상 |
| 스폰서 | Almirall, S.A. |
| 상태 | 완료 |
| 참여자 수 | 260 명 |
| 중재(약물) | Lebrikizumab |
| 시작일 | 2023년 11월 20일 |
| 완료일 | 2025년 6월 25일 |
| 결과 공개일 | 2026년 7월 17일 |
요약
The main purpose of this study is to evaluate the effectiveness of 24 weeks of lebrikizumab in improving disease severity, signs, and symptoms in adults and adolescents with moderate-to-severe atopic dermatitis (AD).
Percentage of Participants Who Achieved Eczema Area and Severity Index (EASI) Total Score Less Than or Equal to (<=) 7 at Week 24
| Lebrikizumab | 74.7 Percentage of participants |
|---|
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moder — LEO Pharma
- A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis — Eli Lilly and Company
- Aquacel Hypersensitivity Dressing in TJAs — Rush University Medical Center
- A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Par — Amgen
- A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE) — Amgen
- A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic D — Amgen